Latest News On Obesity

Latest California Healthline Stories

A Revolutionary Drug for Extreme Hunger Offers Clues to Obesity’s Complexity

A new drug is helping families who’ve spent years padlocking fridges, chaining garbage cans, and hiding food as their children with Prader-Willi syndrome deal with unrelenting hunger. But additional progress — and a broader understanding of obesity — is now under threat as the government dismantles the pipeline for promising new research.

Trump Won’t Force Medicaid To Cover GLP-1s for Obesity. A Few States Are Doing It Anyway.

Late last year, South Carolina Medicaid approved a class of medications known as GLP-1s to treat obesity, placing it among the few state programs covering these effective but expensive drugs. But access remains limited, even for patients covered by Medicaid, because of stringent prerequisites that must be satisfied before starting the drug.

How Little Denmark Got Homegrown Giant Novo Nordisk To Lower Ozempic Prices

As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark — Ozempic maker Novo Nordisk’s home — has limited coverage of the drug after cost overruns “emptied all the money boxes in the entire public health system.

Why Millions Are Trying FDA-Authorized Alternatives to Big Pharma’s Weight Loss Drugs

Although Novo Nordisk and Lilly lump together the pharmacies that compound semaglutide and tirzepatide with internet cowboys selling fake drugs, there is a distinction. The FDA has offered Americans little clarity about the vast gray and black markets for the drugs.

High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Treatment

The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.

Personas de bajos ingresos no pueden recibir terapias efectivas contra la diabetes por el alto costo

La escasez de suministros y las barreras que ponen las aseguradoras para obtener esta poderosa clase de medicamentos, llamados agonistas de GLP-1, han dejado a muchas personas que viven con diabetes y obesidad sin los medicamentos que necesitan para mantenerse saludables.

Arkansas Led the Nation in Measuring Obesity in Kids. Did It Help?

For more than 20 years, children in Arkansas have been measured in school as part of a statewide effort to reduce childhood obesity. But the letters have had no impact on weight loss — and obesity rates have risen. Still, the practice of sending letters has spread to other states.